We are pleased to confirm that on Thursday 10th December 2009, Epistem received the UK Trade & Investment “Internationalise your Business” Award. UKTI presents this award to the company which it judges has been most successful in expanding into new markets. Nominee companies are established companies who have extended their footprint with UKTI assistance, notably through the UKTI Tradeshow Access Programme.
Epistem, led by Matthew Walls CEO, is extremely pleased to have been honoured with this award which reflects the rapid recent expansion of its business, working with larger pharmaceutical companies in new overseas markets building on the successful presence which it has achieved in the UK.
Epistem is a biotechnology company commercialising its expertise in epithelial stem cells in the areas of oncology, gastrointestinal and dermatological diseases. Epistem develops innovative therapeutics and biomarkers and provides contract research services to drug development companies. The Group’s expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. Epistem does not conduct research in the areas of embryonic stem cells or stem cell transplantation
